DNA Microarray Companies | Forecast by 2033


20 Sep 2024

The global DNA microarray market surpassed USD 2.28 billion in 2023 and is estimated to attain around USD 5.60 billion by 2033, poised to grow at a CAGR of 9.4% during the forecast period. The increasing adoption of DNA microarrays for various applications is expected to drive the growth of the DNA microarray market.

DNA Microarray Market Statistics

 

The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/3648

Market Overview

The DNA microarray market develops microarray chips commonly referred to as biochip. A DNA microarray is widely referred to as a gene chip or biochip. It is an arrangement of microscopic DNA fragments compiled to a solid surface for quick measurement of gene expression levels. DNA microarrays find wide applications within various sectors and fields, from cancer detection to proteomics and gene expression.

The rising revolution in information technology, such as software, increasing utilization of this technology in its detection, and the increasing prevalence of cancer globally are expected to enhance the growth of the DNA microarray market during the forecast period.

In addition, growing continuous advancements in DNA microarray technology, expanding applications in research and clinical diagnostics, increasing demand for individualized treatment, and rising funding in genomics research are further anticipated to accelerate the growth of the market during the forecast period.

  • The increasing prevalence of genetic illness and the demand for high throughput and effective techniques are expected to drive market growth.
  • The continuous technological advancements in the DNA microarray have contributed to its growth.
  • The growing emphasis on the adoption of microarray data with other omics technologies such as metabolomics and proteomics is further expected to enhance the growth of the DNA microarray market during the forecast period.

Increasing prevalence of genetic disorders to fuel market growth

The prevalence of genetic diseases significantly increases the market growth of the DNA microarray. The rising prevalence of genetic diseases necessitates early and accurate diagnosis, a role in which DNA microarrays exceed. DNA microarrays play an important role in recognizing genetic markers connected to these diseases and allowing personalized treatment and timely interventions.

This increasing demand for precise diagnostics and genetic testing enhances the widespread adoption of microarray technology, developing it as a vital tool in meeting the healthcare challenges created by genetic diseases, ultimately driving outcomes and patient care. Thus, these factors are expected to drive the growth of the DNA microarray market.

However, data complexity and quality control concerns may restrain market growth.

Data complexity creates a significant challenge in the DNA microarray market. The huge amount of data created by microarray experiments needs advanced expertise and bioinformatics tools for analysis. Handling complicated datasets can be resource-intensive and time-consuming, restraining accessibility to a wider range of healthcare and research facilities.

In addition, misuse of intricate data can emphasize the need for skilled professionals to make erroneous conclusions. Meeting these challenges is necessary to fully harness the potential of DNA microarrays in genomics diagnostics and research. Furthermore, quality control issues pose a significant challenge. These factors are expected to restrain the growth of the DNA microarray market.

DNA Microarray Market Top Companies

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Nucleus Genomics
  • Acenstry
  • Bio-Rad Laboratories, Inc.
  • Roche Diagnostics
  • Qiagen N.V.
  • Oxford Gene Technology (OGT)
  • Applied Microarrays, Inc.
  • Eurofins Genomics LLC
  • LC Sciences
  • Microarrays Inc.
  • Arrayit Corporation
  • BioCat GmbH
  • Savyon Diagnostics Ltd.

Recent Innovation in DNA Microarray by Nucleus Genomics

  • In March 2025, to bring the benefits of personalized medicine to everyone, the next-generation genetic testing and analysis company, Nucleus Genomics, launched a DNA analysis product. Health and DNA are inextricably connected to the healthcare sector. The aim behind this launch was to cure chronic diseases such as type 2 diabetes, breast cancer, and many more with the help of microarray genetic testing.

Recent Innovation in DNA Microarray by Ancestry

  • In September 2023, the global leader in consumer DNA testing and family history, Ancestry launched its first product Pet DNA providing a don DNA test in the US. Pet DNA leveraged the DNA technology and science expertise from Ancestry to provide dog owners a greater understanding of to provide optimal care to consumer’s pets. This company used DNA microarray technology testing.

Regional Insights

Asia Pacific is expected to grow fastest during the forecast period. The increasing collaborations between global pharmaceutical and biotechnology companies and growing government investments in genomics healthcare and research infrastructure are driving the growth of the DNA microarray market in the Asia Pacific. In addition, the rising need for personalized medicine and the increasing prevalence of genetic diseases are further anticipated to enhance market growth.

China, India, Japan, and South Korea are the leading countries in the region. China is the first leading country in the healthcare sector in the world. The application of DNA microarray assay has revolutionized the new era, leading to advanced innovations in omics technologies in China. China is actively focusing on the characterization and summary of traditional Chinese medicine. Thus, these factors are expected to enhance the growth of the market in the Asia Pacific region during the forecast period.

North America dominated the DNA microarray market in 2023. The market for DNA microarray is driven by increasing robust investment in advanced research and development activities, increasing government initiatives supporting genomics research, and growing strategic collaborations between industry leaders and research institutions.

In addition, the well-established regulatory frameworks and strong healthcare infrastructure for medical devices ensure the compliance and timely adoption of DNA microarrays in clinical practices, contributing to the growth of the market. The U.S. and Canada are the emerging countries in the region and are expected to enhance the growth of the DNA microarray market in North America.

  • For instance, In August 2023, the world leader in serving science, Thermo Fisher Scientific, launched a new chromosomal microarray designed to optimize cytogenetic research lab profitability, efficiency, and productivity with an industry-leading two-day turnaround time. The Applied Biosystems™ CytoScan HD Accel array provides improved coverage in more than 5,000 critical genome regions and analyzes the whole human genome by providing insights on chromosomal variants for a wide range of prenatal.

Market Potential and Growth Opportunity

DNA microarray technology has revolutionized various industries such as healthcare, pharmaceuticals, and agriculture by providing detailed genetic insights. DNA microarray helps in the early detection and treatment of genetic diseases in healthcare and advantages millions globally.

The Food and Agriculture Organization represents its effect on improving crop resilience and productivity in agriculture practices, according to the U.S. Food and Drug Administration. The rising technological advancements and growing applications in healthcare and research accelerate the significant growth in the market. Thus, these factors are anticipated to drive the growth of the DNA microarray market in the coming years.

DNA Microarray Market News

  • In July 2023, a company spearheading the field of commercializing epigenetic biomarker technology, Foxo Technologies, launched its Bioinformatics Services. The aim behind this launch was to accelerate breakthroughs in healthcare, biotechnology, and biology and maintain the growing field of epigenetic research. FOXO company added that any research group searching to use DNA methylation microarrays can benefit from FOXO’s Bioinformatics Services.
  • In January 2024, the new Axiom™ PangenomiX Array*, its most ethnically diverse array to taste, was launched by Thermo Fisher Scientific. This new array offered genetic coverage for pharmacogenomic research and population-scale disease studies.

DNA Microarray Market Highlights

Report Attribute Key Statistics
Market Revenue in 2024 USD 2.49 Billion
Market Revenue by 2033 USD 5.60 Billion
CAGR 9.4%
Quantitative Units Revenue in USD million/billion, Volume in units
Largest Market North America
Base Year 2023
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Segmentation

By Type

  • Complementary DNA Microarrays
  • Oligonucleotide DNA Microarrays
  • Others

By Application

  • Gene Expression Analysis
  • Genotyping
  • Others

By End-user

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Centers
  • Hospitals and Clinics
  • Academic and Research Institute
  • Others

Buy this Research Report@ https://www.precedenceresearch.com/checkout/3648

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Related Reports